---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-22-000137"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T12:57:35.264261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q3 revenue up 25% to $75.6M; net loss improves 38%

## Summary
- Total revenue $75.6M (+25% YoY), test volume 26,374 (+26% YoY).
- Net loss $8.7M improves 38% YoY; diluted EPS -$0.12 improves 40% YoY.
- Non-GAAP gross margin 66% vs 64% prior year; operating cash flow $7.0M in Q3.
- Decipher Prostate gets NCCN Level 1 evidence; commercial coverage expanded to 195M lives for Decipher, 230M for Afirma.
- Ended Q3 with $170.1M cash; appointed Dr. Eliav Barr to board, John Leite as GM Pulmonology.

## SEC filing metadata
- accession: 0001384101-22-000137
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000137/0001384101-22-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000137/vcyt-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-22-000137
- JSON: https://secwatch.observer/filing/0001384101-22-000137.json
- Plain text: https://secwatch.observer/filing/0001384101-22-000137.txt

## Key facts
- Earnings Releases
  VERACYTE, INC. reported the third quarter ended September 30, 2022 results: revenue $75.6 million, net income $8.7 million, EPS $0.12.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $75.6 million
  - Net income: $8.7 million
  - EPS: $0.12
  - Result: reported results
  source text: Total revenue for the third quarter of 2022 was $75.6 million, an increase of 25% compared to $60.4 million in the third quarter of 2021. Testing revenue was $64.6 million, an increase of 27% compared to $50.9 million in the third quarter of 2021 driven primarily by the strong performance of our Decipher and Afirma tests. Product revenue was $3.3 million, an increase of 12% compared to $3.0 million in the third quarter of 2021. Biopharmaceutical and other revenue was $7.7 million, an increase of 18% compared to $6.5 million in the third quarter of 2021, driven primarily by the contribution of the HalioDx acquisition. Total gross margin for the third quarter of 2022, including the amortization of acquired intangible assets, was 59%, compared to 57% in the third quarter of 2021. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 66%, compared to 64% in the third quarter of 2021. Operating expenses, excluding cost of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000137/0001384101-22-000137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.